Photodiagnosis and Photodynamic Therapy
Volume 5, Issue 4 , Pages 276-284 , December 2008

Pharmacokinetic modeling of motexafin gadolinium disposition in mouse tissues using optical pharmacokinetic system measurements

  • Stephen C. Kanick, PhD

      Affiliations

    • Department of Chemical Engineering, University of Pittsburgh School of Engineering, Pittsburgh, PA 15261, United States
    • ,
  • Julie L. Eiseman, PhD

      Affiliations

    • Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States
    • Molecular Therapeutics and Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, United States
    • ,
  • Robert S. Parker, PhD

      Affiliations

    • Department of Chemical Engineering, University of Pittsburgh School of Engineering, Pittsburgh, PA 15261, United States
    • Molecular Therapeutics and Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, United States
    • Corresponding Author InformationCorresponding author at: Department of Chemical and Petroleum Engineering, University of Pittsburgh Swanson School of Engineering, 1249 Benedum Hall, Pittsburgh, PA 15261, United States.

References 

  1. Sibata CH, Colussi VC, Oleinick NL, Kinsella TJ. Photodynamic therapy in oncology. Expert Opin Pharmacother. 2001;2:917–927
  2. Moan J. Properties of optimal PDT sensitizers. J Photochem Photobiol B. 1990;5:521–524
  3. Solban N, Rizvi I, Hasan T. Properties of optimal PDT sensitizers. Lasers Surg Med. 2006;38:522–531
  4. Hopper C. Photodynamic therapy: a clinical reality in the treatment of cancer. Lancet Oncol. 2000;1:212–219
  5. Young SW, Qing F, Harriman A, et al. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci. 1996;93:6610–6615
  6. Evens AE. Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. Curr Opin Oncol. 2004;16:576–580
  7. Miller RA, Woodburn K, Fan Q, Renschler MF, Sessler JL, Koutcher JA. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys. 1999;45:981–989
  8. Viala J, Vanel D, Meingan P, Lartigau E, Carde P, Renschler M. Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable by MR imaging: preliminary results in brain metastases. Radiology. 1999;212:755–759
  9. Rosenthal DI, Nurenberg P, Becerra CR, et al. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res. 1999;5(4):739–745
  10. Bernhard EJ, Mitchell JB, Deen D, Cardell M, Rosenthal DI, Brown JM. Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent. Cancer Res. 2000;60:86–91
  11. Carde P, Timmerman R, Mehta MP, et al. Multicenter phase Ib/II rrial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol. 2001;19:2072–2083
  12. Xu S, Zakian K, Thaler H, et al. Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int J Radiat Oncol Biol Phys. 2001;49:1381–1390
  13. Dehnad H, Kal HB, Stam T, Gademan IS, van Moorselaar RJA, van der Sanden BPJ. Response to motexafin gadolinium and ionizing radiation of experimental rat prostate and lung tumors. Int J Radiation Oncol Biol Phys. 2003;57:787–793
  14. Evens AM, Lecane P, Magda D, et al. Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. Neoplasia. 2005;105:1265–1273
  15. Miller RA, Woodburn KW, Fan Q, et al. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin Cancer Res. 2001;7:3215–3221
  16. Ramos J, Sirisawad M, Miller R, Naumovski L. Motexafin gadolinium modulates levels of phosphorylated akt and synergizes with inhibitors of akt phosphorylation. Mol Cancer Ther. 2006;5:1176–1182
  17. William Jr. WN, Zinner RG, Karp DD, et al. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer. J Thorac Oncol. 2007;2:745–750
  18. Boswell GW, Miles DR, Thiemann PA, Mesfin M. Population pharmacokinetics and bioavailability of motexafin gadolinium (Xcytrin®) in CD1 mice following intravenous and intraperitoneal injection. Invest New Drugs. 2006;24:281–289
  19. Kanick SC, Eiseman JL, Joseph E, Guo J, Parker RS. Noninvasive and nondestructive optical spectroscopic measurement of motexafin gadolinium in mouse tissues: Comparison to high-performance liquid chromatography. J Photochem Photobiol B. 2007;88:90–104
  20. Mourant JR, Johnson TM, Los G, Bigio IJ. Non-invasive measurement of chemotherapy drug concentrations in tissue: Preliminary demonstrations of in vivo measurements. Phys Med Biol. 1999;44:1397–1417
  21. Canpolat M, Mourant JR. Monitoring photosensitizer concentration by use of a fiber-optic probe with small source-detector separation. Appl Opt. 2000;39:6508–6514
  22. Reif R, Wang M, Joshi S, A’Amar O, Bigio IJ. Optical method for real-time monitoring of drug concentrations facilitates the development of novel methods for drug delivery to brain tissue. J Biomed Opt. 2007;12:034036
  23. Parise RA, Miles DR, Egorin MJ. Sensitive high-performance liquid chromatographic assay for motexafin gadolinium and motexafin lutetium in human plasma. J Chromatogr B: Biomed Sci Appl. 2000;749:145–152
  24. Gerlowski LE, Jain RK. Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci. 1983;72:1103–1127
  25. E. Carson, C. Cobelli (Eds.), Modelling Methodology for Physiology and Medicine, Academic Press, San Diego, 2001.
  26. US EPA Office of Health and Environmental Assessment by the International Life Sciences Institute. Physiological parameter values for PBPK models; 1984.
  27. Akaike H. A new look at the statistical model identification. IEEE Trans Aut Control. 1974;AC-19(6):716–723
  28. MathWorks Inc. Matlab statistics toolbox 6 user’s guide. Natick (MA); 2007.
  29. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res. 1989;37:77–104
  30. Netti PA, Baxter LT, Boucher Y, Skalak R, Jain RK. Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res. 1995;55:5451–5458

PII: S1572-1000(08)00107-5

doi: 10.1016/j.pdpdt.2008.11.005

Photodiagnosis and Photodynamic Therapy
Volume 5, Issue 4 , Pages 276-284 , December 2008

Article Tools

* Image Usage & Resolution